Aspen Pharmacare is targeting regulatory approval in Canada for its generic GLP-1 obesity treatment by September, positioning itself to enter the market soon after the expiry of key patent protections on Novo Nordisk’s semaglutide. The Durban-based drugmaker expects approval between May and September for its version of semaglutide, the active ingredient in Ozempic, following the lapse of patent protection in Canada after missed maintenance fee payments and the expiry of data exclusivity in January.
Canada is expected to serve as Aspen’s first launch market, providing a regulatory reference point for expansion into Latin America and the Middle East, where authorities often rely on decisions by established regulators. Early market entry is considered critical in the generics sector, particularly in high-demand therapeutic categories such as obesity and diabetes, where price competition intensifies rapidly after patent expiry.
The global GLP-1 market has expanded sharply in recent years, driven by rising obesity rates and strong uptake of branded treatments including Ozempic and Eli Lilly’s Mounjaro. Aspen already distributes Mounjaro in South Africa, where the product has contributed meaningfully to growth. However, the economics of generics are expected to differ, with as many as a dozen manufacturers likely to compete in Canada, placing downward pressure on pricing.
READ – Aspen Pharmacare Secures Substantial Gain from Unexpected Asia-Pacific Divestment
Despite the anticipated competition, Aspen expects significant volumes and views GLP-1 therapies as a long-term growth driver. The company has invested in manufacturing capacity to support production at scale and has reduced debt levels, creating flexibility in capital allocation.
According to JSE Market Data, Aspen’s shares have gained 16% year to date, closing 0.5% higher following the announcement.
First-half revenue declined 4.1% to R21.1bn, reflecting ongoing portfolio adjustments and currency dynamics. However, management expects lower-priced generics to unlock demand, particularly in emerging markets where patients often fund treatment privately and affordability remains a constraint.
The opportunity follows the expiry of the core semaglutide patent originally filed in 2006. According to Health Canada Regulatory Filings, Canada was among the first jurisdictions where patent protection lapsed, creating a pathway for generic entrants once exclusivity provisions expired. With regulatory review under way, Aspen is seeking to establish an early foothold in a therapeutic segment that continues to expand globally.